source
- Axoltis Phase 2 ALS Trial Fails Primary Endpoint Though Shows Some Secondary TrendsAxoltis Pharma reported that its phase 2 study of the synthetic peptide NX210c in amyotrophic lateral sclerosis did not meet its primary goal. The double‑blind, randomized trial enrolled 82 French…
- Opinion: Restoring public trust in science requires humility and collaboration, not just better messagingMichelle Groman and Caroline Montojo, presidents of The Greenwall Foundation and the Dana Foundation, wrote an opinion piece on Sept. 14, 2026 about the challenge of rebuilding public trust in scie…